ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.630
+0.040 (1.54%)
Dec 20, 2024, 4:00 PM EST - Market closed
ProQR Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Dec '24 Dec 20, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 271 | 161 | 264 | 570 | 211 | 476 | |
Market Cap Growth | 41.28% | -39.20% | -53.63% | 170.61% | -55.73% | -22.13% | |
Enterprise Value | 191 | 56 | 187 | 430 | 145 | 406 | |
Last Close Price | 2.63 | 1.98 | 3.70 | 8.01 | 4.20 | 9.91 | |
PS Ratio | 10.46 | 22.05 | 56.74 | 210.75 | 167.32 | 219.30 | |
PB Ratio | 7.71 | 3.51 | 3.71 | 4.43 | 3.04 | 4.52 | |
P/TBV Ratio | 5.34 | 3.51 | 3.69 | 4.40 | 3.02 | 4.49 | |
P/FCF Ratio | - | 7.21 | - | - | - | - | |
P/OCF Ratio | - | 6.75 | - | - | - | - | |
EV/Sales Ratio | 9.32 | 7.63 | 40.19 | 158.93 | 115.23 | 187.34 | |
EV/FCF Ratio | - | 2.49 | - | - | - | - | |
Debt / Equity Ratio | 0.70 | 0.48 | 0.33 | 0.53 | 0.61 | 0.14 | |
Debt / FCF Ratio | - | 0.98 | - | - | - | - | |
Asset Turnover | 0.15 | 0.04 | 0.02 | 0.02 | 0.01 | 0.02 | |
Quick Ratio | 2.29 | 3.51 | 7.24 | 6.83 | 7.44 | 10.29 | |
Current Ratio | 2.33 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | |
Return on Equity (ROE) | -67.13% | -51.33% | -71.37% | -71.62% | -62.00% | -60.85% | |
Return on Assets (ROA) | -14.86% | -14.06% | -21.38% | -23.20% | -29.36% | -31.53% | |
Return on Capital (ROIC) | -33.63% | -29.04% | -31.06% | -27.04% | -32.03% | -34.28% | |
Earnings Yield | -9.84% | -19.34% | -26.05% | -12.12% | -27.04% | -13.32% | |
FCF Yield | -13.16% | 13.88% | -27.99% | -5.29% | -27.87% | -10.51% | |
Buyback Yield / Dilution | -3.44% | -13.08% | -11.62% | -28.21% | -21.99% | -20.51% | |
Total Shareholder Return | -3.44% | -13.08% | -11.62% | -28.21% | -21.99% | -20.51% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.